Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $1,104 | $975 | $0 | $0 |
| % Growth | 13.2% | – | – | – |
| Cost of Goods Sold | $2,358 | $56 | $1,318 | $0 |
| Gross Profit | -$1,254 | -$54,992 | -$1,318 | $0 |
| % Margin | -113.6% | -5,640.2% | – | – |
| R&D Expenses | $67,803 | $55,967 | $64,232 | $42,062 |
| G&A Expenses | $20,968 | $23,882 | $22,428 | $18,621 |
| SG&A Expenses | $20,968 | $23,882 | $22,428 | $18,621 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,358 | -$55,967 | $0 | -$256 |
| Operating Expenses | $86,413 | $23,882 | $86,660 | $60,683 |
| Operating Income | -$87,667 | -$78,874 | -$86,660 | -$60,683 |
| % Margin | -7,940.9% | -8,089.6% | – | – |
| Other Income/Exp. Net | -$2,621 | -$2,746 | $329 | -$1,061 |
| Pre-Tax Income | -$90,288 | -$81,620 | -$86,331 | -$61,744 |
| Tax Expense | $0 | $0 | $0 | -$56 |
| Net Income | -$90,288 | -$81,620 | -$85,013 | -$61,744 |
| % Margin | -8,178.3% | -8,371.3% | – | – |
| EPS | -2.16 | -2.44 | -3.31 | -2.1 |
| % Growth | 11.5% | 26.3% | -57.6% | – |
| EPS Diluted | -2.16 | -2.44 | -3.31 | -2.1 |
| Weighted Avg Shares Out | 41,860 | 33,450 | 25,703 | 29,395 |
| Weighted Avg Shares Out Dil | 41,860 | 33,450 | 25,703 | 29,395 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $249 | $1,693 | $1,118 |
| Interest Expense | $2,838 | $2,802 | $977 | $1,005 |
| Depreciation & Amortization | $2,575 | $1,823 | $1,318 | $792 |
| EBITDA | -$85,092 | -$76,995 | -$84,036 | -$59,029 |
| % Margin | -7,707.6% | -7,896.9% | – | – |